NASHVILLE, Tenn. and SAN ANTONIO, June 2, 2025 /PRNewswire/ -- OneOncology, a physician-led national platform empowering independent oncology practices, and...
Peer-reviewed journal article highlights need for personalized, culturally relevant approaches to cognitive care and research BOSTON, June 2, 2025 /PRNewswire/...
PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered...
-Clinical benefit and favorable safety profile as monotherapy and in combination with SOC- -Biomarker data supports MOA: decreased GBM mesenchymal...
- Expert Insights on Clinical Relevance and Scientific Rationale- The replay of the event is available on the Investor Relations...
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable...
All dollar amounts reflected in Canadian dollars unless otherwise statedVANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics...
Presentation highlights deep and durable responses and radiographic resolution of bone metastases in patients with advanced prostate cancer Final clinical...
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7...
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed...
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"),...
The AI-enabled clinical assistant is available to query patient data across the EHR as well as build custom agents to...
33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year...
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1...
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced...
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)...
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to...
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver...
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the...
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable...